Skip to content

Epitalon

epitalonepithalonepithalamin

Khavinson tetrapeptide. Telomerase research; effects accumulate over cycles, short-protocol courses.

Half-life
30 min
Out of system
~3 h
Route
Subcutaneous
Level
Intermediate

Very short-acting — protocols dose 1–2× a day. After the last dose, roughly 97% has cleared in ~3 h (five half-lives) — the window that matters for washouts, bloodwork and surgery.

What Epitalon is used for

  • Khavinson tetrapeptide — telomerase research and pineal effects
  • Reported sleep quality + circadian benefits
  • Cycled, not chronic

How it's typically used

Research range: 5 mg subcutaneous daily, 10–20 day course, repeat 1–2× per year.

What to watch for

  • Western human evidence is thin
  • Effects are subtle and accumulate over multiple cycles
  • Sourcing quality is critical with Russian peptides

About Longevity

What they are
Compounds studied for cellular ageing — mitochondrial function, senescent-cell clearance, telomere and autophagy pathways.
How they're run
Mixed routes: some injected in short annual or biannual courses, others taken orally every day.
What to watch
Endpoints here are measured in decades, so nobody has human outcome data. Bloodwork and function markers are the only feedback you will get in a realistic timeframe.

Full guide

Epitalon: Tracking a Longevity-Focused Protocol

Epitalon protocols last days, not weeks, and effects accumulate across cycles. Here is what to track if you want personal data that compounds over years.

Other longevity

Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.